earnings
confidence high
sentiment negative
materiality 0.80
PetMed Express warns Q2 net sales down ~25% YoY; receives Nasdaq delisting notice
PETMED EXPRESS INC
2026-Q2 EPS reported
-$2.05
revenue$95,544,000
- Preliminary Q2 net sales estimated at $43.4M-$44.5M vs $58.0M (restated) prior year.
- Six-month net sales estimated at $94.5M-$95.6M vs $124.3M (restated) prior year.
- Cannot estimate operating income due to pending goodwill impairment analysis.
- Cash $36.1M, no debt as of September 30, 2025.
- Nasdaq non-compliance for late Q1 and Q2 10-Qs; compliance plan update due by Nov 28, 2025.